IN THE UNITED STATES DISTRICT COURT FOR THE
NORTHERN DISTRICT OF OKLAHOMA

PETER POE, et al.,

Plaintiffs,

v.

GENTNER DRUMMOND, et al.,

Defendants.

Case No. 4:23-cv-00177-JFH-SH

BRIEF OF AMICI CURIAE AMERICAN ACADEMY OF PEDIATRICS
AND ADDITIONAL NATIONAL AND STATE MEDICAL AND MENTAL
HEALTH ORGANIZATIONS IN SUPPORT OF PLAINTIFFS’ MOTION
FOR PRELIMINARY INJUNCTION
CORPORATE DISCLOSURE STATEMENT

Pursuant to Federal Rule of Civil Procedure 7.1, the undersigned counsel for American Academy of Pediatrics ("AAP"), the Academic Pediatric Association ("APA"), the American Academy of Child & Adolescent Psychiatry ("AACAP"), the American Academy of Family Physicians ("AAFP"), the American Academy of Nursing ("AAN"), the American Association of Physicians for Human Rights, Inc. d/b/a GLMA: Health Professionals Advancing LGBTQ+ Equality ("GLMA"), the American College of Obstetricians and Gynecologists ("ACOG"), the American College of Osteopathic Pediatricians ("ACOP"), the American College of Physicians ("ACP"), the American Medical Association ("AMA"), the American Pediatric Society ("APS"), Association of Medical School Pediatric Department Chairs, Inc. ("AMSPDC"), the Endocrine Society ("ES"), the Oklahoma Chapter of the American Academy of Pediatrics ("OKAAP"), the National Association of Pediatric Nurse Practitioners ("NAPNAP"), the Oklahoma Council of Child and Adolescent Psychiatry ("OKCCAP"), the Pediatric Endocrine Society ("PES"), the Societies for Pediatric Urology ("SPU"), the Society for Adolescent Health and Medicine ("SAHM"), the Society for Pediatric Research ("SPR"), the Society of Pediatric Nurses ("SPN"), and the World Professional Association for Transgender Health ("WPATH") certify that:

1. AAP, APA, AACAP, AAFP, AAN, GLMA, ACOG, ACOP, ACP,
AMA, APS, AMSPDC, ES, OKAAP, NAPNAP, OKCCAP, PES, SPU, SAHM, SPR, SPN, and WPATH, respectively, have no parent corporation.

2. No corporations hold any stock in AAP, APA, AACAP, AAFP, AAN, GLMA, ACOG, ACOP, ACP, AMA, APS, AMSPDC, ES, OKAAP, NAPNAP, OKCCAP, PES, SPU, SAHM, SPR, SPN, and WPATH.¹

¹ A disclosure statement per Form CV-24 does not accompany this brief because amici curiae do not fall within the definition of “parties” under Local Civil Rule 7.1.
**TABLE OF CONTENTS**

Corporate Disclosure Statement .............................................................................................................. ii

Table of Contents ................................................................................................................................. iv

Table of Authorities .............................................................................................................................. vi

STATEMENT OF INTEREST OF *AMICI CURIAE* ................................................................. 1

INTRODUCTION ................................................................................................................................. 3

ARGUMENT ........................................................................................................................................ 5

I. Understanding Gender Identity and Gender Dysphoria ............................................................. 5

II. The Widely Accepted Guidelines for Treating Adolescents with Gender Dysphoria Provide for Medical Interventions When Indicated ........ 8

   A. The Gender Dysphoria Treatment Guidelines Include Thorough Mental Health Assessments and, for Some Adolescents, Medical Interventions ................................................................. 9

      1. A Robust Diagnostic Assessment Is Required Before Medical Interventions Are Provided ................................................................. 10

      2. The Guidelines Recommend Only Non-Medical Interventions for Prepubertal Children With Gender Dysphoria ................................................................. 11

      3. In Certain Circumstances, the Guidelines Provide for the Use of Medical Interventions to Treat Adolescents With Gender Dysphoria ................................................................. 11

   B. The Guidelines for Treating Gender Dysphoria Were Developed Through a Robust and Transparent Process, Employing the Same Scientific Rigor That Underpins Other Medical Guidelines ................................................................................................................................. 15

   C. Scientific Evidence Indicates the Effectiveness of Treating Gender Dysphoria According to the Guidelines ................................................................. 17
III. The Healthcare Ban Would Irreparably Harm Many Adolescents with
Gender Dysphoria By Denying Them the Treatment They Need.............. 21

CONCLUSION....................................................................................................... 22
TABLE OF AUTHORITIES

Cases

*Brandt v. Rutledge,*
  551 F. Supp. 3d 882 (E.D. Ark. 2021)................................................................ 21

*Brandt ex rel. Brandt v. Rutledge,*
  47 F.4th 661 (8th Cir. Aug. 25, 2022)................................................................ 21

*Doe v. Ladapo,*
  -- F. Supp. 3d --, 2023 WL 3833848 (N.D. Fla. June 6, 2023) ......................... 21

Other Authorities

Am. Psychiatric Ass’n, *Diagnostic and Statistical Manual of Mental Disorders: DSM-5 – TR* ........................................................................................................ 7

Am. Psychological Ass’n, *Guidelines for psychological practice with transgender and gender nonconforming people,* 70(9) AMERICAN PSYCHOLOGIST 832 (2015),


  https://pubmed.ncbi.nlm.nih.gov/32368216..................................................17, 18

Stewart L. Adelson, *Practice Parameter on Gay, Lesbian, or Bisexual Sexual Orientation, Gender Nonconformity, and Gender Discordance in Children and Adolescents,* 51 J. AM. ACAD. CHILD & ADOLESCENT PSYCHIATRY 957, 964 (2020),

Zoe Aldridge et al., *Long Term Effect of Gender Affirming Hormone Treatment on Depression and Anxiety Symptoms in Transgender*
People: A Prospective Cohort Study, 9 ANDROLOGY 1808–16 (2021) .................................................................................................................. 18


Polly Carmichael et al., Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK, 16(2) PLOS ONE e0243894 (2021), https://pubmed.ncbi.nlm.nih.gov/33529227 ............................................. 17

Diane Chen et al., Psychosocial Functioning in Transgender Youth after 2 Years of Hormones, 388(3) NEW ENG. J. MED 240–50 (2023) ............................................................................................................ 18, 19


Endocrine Society, Methodology, https://www.endocrine.org/clinical-practice-guidelines/methodology ....................................................... 16

Amy E. Green et al., Association of Gender-Affirming Hormone Therapy with Depression, Thoughts of Suicide, and Attempted Suicide Among Transgender and Nonbinary Youth, J. ADOLESCENT HEALTH (2021), https://www.jahonline.org/article/S1054-139X(21)00568-1/fulltext


Rittakerttu Kaltiala et al., Adolescent development and psychosocial functioning after starting cross-sex hormones for gender dysphoria, 74(3) NORDIC J. PSYCHIATRY 213 (2020)

Brayden N. Kameg & Donna G. Nativio, Gender dysphoria in youth:


Jack L. Turban et al., *Pubertal suppression for transgender youth and risk of suicidal ideation*, 145(2) PEDIATRICS e20191725 (2020), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073269..............................17, 19, 21

STATEMENT OF INTEREST OF AMICI CURIAE

Amici curiae are the American Academy of Pediatrics, the Academic Pediatric Association, the American Academy of Child & Adolescent Psychiatry, the American Academy of Family Physicians, the American Academy of Nursing, the American Association of Physicians for Human Rights, Inc. d/b/a GLMA: Health Professionals Advancing LGBTQ+ Equality, the American College of Obstetricians and Gynecologists, the American College of Osteopathic Pediatricians, the American College of Physicians, the American Medical Association, the American Pediatric Society, Association of Medical School Pediatric Department Chairs, Inc., the Endocrine Society, the Oklahoma Chapter of the American Academy of Pediatrics, the National Association of Pediatric Nurse Practitioners, the Oklahoma Council of Child and Adolescent Psychiatry, the Pediatric Endocrine Society, the Societies for Pediatric Urology, the Society for Adolescent Health and Medicine, the Society for Pediatric Research, the Society of Pediatric Nurses, and the World Professional Association for Transgender Health (collectively, “amici”).

Amici are professional medical and mental health organizations seeking to ensure that all adolescents, including those with gender dysphoria, receive the

2 Plaintiffs have consented to the filing of this brief. Defendants do not oppose the filing of this brief. Amici affirm that no counsel for a party authored this brief in whole or in part and that no person other than amici or their counsel made any monetary contributions intended to fund the preparation or submission of this brief.
optimal medical and mental health care they need and deserve. *Amici* represent thousands of healthcare providers who have specific expertise with the issues raised in this brief. The Court should consider *amici*’s brief because it provides important expertise and addresses misstatements about the treatment of transgender adolescents.
INTRODUCTION

On May 1, 2023, the Oklahoma Governor signed S.B. 613 (the “Healthcare Ban”), a law that prohibits healthcare providers from providing patients under 18 with critical, medically necessary, evidence-based treatments for gender dysphoria, and makes the provision of such treatments a felony.\(^3\) Denying such evidence-based medical care to adolescents who meet the requisite medical criteria puts them at risk of significant harm. Below, \textit{amici} provide the Court with an accurate description of the relevant treatment guidelines and summarize the scientific evidence supporting the medical interventions for adolescents prohibited by the Healthcare Ban.\(^4\)

Gender dysphoria is a clinical condition that is marked by distress due to an incongruence between the patient’s gender identity (i.e., the innate sense of oneself as being a particular gender) and sex assigned at birth. This incongruence can lead to clinically significant distress and impair functioning in many aspects of the patient’s life.\(^5\) If not treated, or treated improperly, gender dysphoria can result in

\(^3\) Okla. S.B. 613 §§ 1(A)(2)(a)(2), (B)–(F) prohibits treatments that delay or stop puberty or include certain hormone therapy which, as discussed in this brief, are medical necessary care for certain adolescents with gender dysphoria, and makes the provision of such treatments a felony.

\(^4\) Because this brief focuses primarily on adolescents, it does not discuss surgeries that are typically available to transgender adults.

\(^5\) See, \textit{e.g.}, Jason Rafferty, \textit{Ensuring Comprehensive Care and Support for Transgender and Gender-Diverse Children and Adolescents}, 142(4) \textit{PEDIATRICS} e20182162, at 2–3, tbl.1 (2018) (hereinafter, “AAP Policy Statement”),
debilitating anxiety, depression, and self-harm, and is associated with higher rates of suicide. As such, the effective treatment of gender dysphoria saves lives.

The widely accepted recommendation of the medical community, including that of the respected professional organizations participating here as *amici*, is that the standard of care for treating gender dysphoria is “gender-affirming care.” Gender-affirming care is care that supports an individual with gender dysphoria as they explore their gender identity—in contrast with efforts to change the individual’s gender identity to match their sex assigned at birth, which are known to be ineffective and harmful. For adolescents with persistent gender dysphoria that worsens with the onset of puberty, gender-affirming care may include medical interventions to align their physiology with their gender identity. Empirical evidence indicates that gender-affirming care, including gender-affirming medical interventions provided to carefully evaluated patients who meet diagnostic criteria, can alleviate clinically significant distress and lead to significant improvements in


6 *Id.* at 10.

the mental health and overall well-being of adolescents with gender dysphoria.8

The Healthcare Ban disregards this medical evidence by precluding healthcare providers from providing adolescent patients with treatments for gender dysphoria in accordance with the accepted standard of care. Accordingly, amici urge this Court to grant Plaintiffs’ motion for a preliminary injunction.

ARGUMENT

This brief first provides background on gender identity and gender dysphoria. It then describes the professionally-accepted medical guidelines for treating gender dysphoria as they apply to adolescents, the scientifically rigorous process by which these guidelines were developed, and the evidence that supports the effectiveness of this care for adolescents with gender dysphoria. Finally, the brief explains how the Healthcare Ban would irreparably harm adolescents with gender dysphoria by denying crucial care to those who need it.

I. Understanding Gender Identity and Gender Dysphoria.

A person’s gender identity is a person’s deep internal sense of belonging to a particular gender.9 Most people have a gender identity that aligns with their sex

9 AAP Policy Statement, supra note 4, at 2 tbl.1.
assigned at birth.\textsuperscript{10} However, transgender people have a gender identity that does not align with their sex assigned at birth.\textsuperscript{11} In the United States, it is estimated that approximately 1.4 million individuals are transgender.\textsuperscript{12} Of these individuals, approximately 10\% are teenagers aged 13 to 17.\textsuperscript{13} Individuals often start to understand their gender identity during prepubertal childhood and adolescence.

Today, there is an increasing understanding that being transgender is a normal variation of human identity.\textsuperscript{14} However, many transgender people suffer from gender dysphoria, a serious medical condition in which the patient experiences significant distress that can lead to “impairment in peer and/or family relationships,
school performance, or other aspects of their life.” Gender dysphoria is a formal diagnosis under the American Psychiatric Association’s Diagnostic and Statistical Manual (DSM-5-TR).\textsuperscript{16}

Adolescents with gender dysphoria are not expected to identify later as their sex assigned at birth.\textsuperscript{17} Instead, “[l]ongitudinal studies have indicated that the emergence or worsening of gender dysphoria with pubertal onset is associated with a very high likelihood of being a transgender adult.”\textsuperscript{18}

If untreated or inadequately treated, gender dysphoria can cause depression, anxiety, self-harm, and suicidality.\textsuperscript{19} Indeed, over 60% of transgender adolescents and young adults reported having engaged in self-harm during the preceding

\textsuperscript{15} AAP Policy Statement, supra note 4, at 3.
\textsuperscript{17} See, e.g., Stewart L. Adelson, Practice Parameter on Gay, Lesbian, or Bisexual Sexual Orientation, Gender Nonconformity, and Gender Discordance in Children and Adolescents, 51 J. AM. ACAD. CHILD & ADOLESCENT PSYCHIATRY 957, 964 (2020), https://pubmed.ncbi.nlm.nih.gov/22917211 (“In contrast, when gender variance with the desire to be the other sex is present in adolescence, this desire usually does persist through adulthood”).
12 months, and over 75% reported symptoms of generalized anxiety disorder in the preceding two weeks.\textsuperscript{20} Even more troubling, more than 50% of this population reported having seriously considered attempting suicide,\textsuperscript{21} and more than one in three transgender adolescents reported having attempted suicide in the preceding 12 months.\textsuperscript{22}

**II. The Widely Accepted Guidelines for Treating Adolescents with Gender Dysphoria Provide for Medical Interventions When Indicated.**

The widely accepted view of the professional medical community is that gender-affirming care is the appropriate treatment for gender dysphoria and that, for some adolescents, gender-affirming medical interventions are necessary.\textsuperscript{23} This care greatly reduces the negative physical and mental health consequences that result

\begin{flushleft}

\textsuperscript{21} See *id.* at 2.


\end{flushleft}
when gender dysphoria is untreated.\textsuperscript{24}

A. The Gender Dysphoria Treatment Guidelines Include Thorough Mental Health Assessments and, for Some Adolescents, Medical Interventions.

The treatment protocols for gender dysphoria are laid out in established, evidence-based clinical guidelines: (i) the Endocrine Society Clinical Practice Guideline for Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons, and (ii) the WPATH Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People (together, the “Guidelines”).\textsuperscript{25} The Guidelines have been developed by expert clinicians and researchers who have worked with patients with gender dysphoria for many years.

The Guidelines provide that all youth with gender dysphoria should be evaluated, diagnosed, and treated by a qualified health care professional (“HCP”). Further, the Guidelines provide that each patient who receives gender-affirming care should receive only evidence-based, medically necessary, and appropriate interventions that are tailored to the patient’s individual needs.

\textsuperscript{24} See id.

1. **A Robust Diagnostic Assessment Is Required Before Medical Interventions Are Provided.**

   According to the Guidelines, gender-affirming care for adolescents begins with a thorough evaluation by a HCP who: (1) is licensed by their statutory body and holds a master’s degree or equivalent in a relevant clinical field; (2) has expertise and received theoretical and evidence-based training in child, adolescent, and family mental health; (3) has expertise and received training in gender identity development, gender diversity in children and adolescents, can assess capacity to consent, and possesses knowledge about gender diversity across the life span; (4) has expertise and received training in autism spectrum disorders and other neurodevelopmental presentations, or collaborates with a developmental disability expert when working with neurodivergent patients; and (5) continues engagement in professional development in areas relevant to gender diverse children, adolescents, and families.\(^{26}\)

   Prior to developing a treatment plan, the HCP should conduct a “comprehensive biopsychosocial assessment” of the adolescent patient.\(^{27}\) The HCP conducts this assessment to “understand the adolescent’s strengths, vulnerabilities, diagnostic profile, and unique needs,” so that the resulting treatment plan is

\(^{26}\)See WPATH Guidelines, *supra* note 24, at S49.

\(^{27}\)Id. at S50.
appropriately individualized.\textsuperscript{28} This assessment must be conducted collaboratively with the patient and their caregiver(s).\textsuperscript{29}

2. \textbf{The Guidelines Recommend Only Non-Medical Interventions for Prepubertal Children With Gender Dysphoria.}

For prepubertal children with gender dysphoria, the Guidelines provide for mental health care and support for the child and their family.\textsuperscript{30} The Guidelines do \textit{not} recommend that any medical interventions (such as puberty blockers, hormone therapy or surgery) be provided to prepubertal children with gender dysphoria.\textsuperscript{31}

3. \textbf{In Certain Circumstances, the Guidelines Provide for the Use of Medical Interventions to Treat Adolescents With Gender Dysphoria.}

For youths with gender dysphoria that continues into adolescence—after the onset of puberty—the Guidelines provide that, in addition to mental health care, medical interventions may be indicated. Before an adolescent may receive any medical interventions for gender dysphoria, a qualified HCP must determine that: (1) the adolescent meets the diagnostic criteria of gender incongruence according to the World Health Organization’s International Classification of Diseases; (2) the

\textsuperscript{28} Id.
\textsuperscript{29} Id.
\textsuperscript{30} See id. at S73–S74; Endocrine Soc’y Guidelines, \textit{supra} note 24, at 3877–78.
\textsuperscript{31} See WPATH Guidelines, \textit{supra} note 24, at S64, S67; Endocrine Soc’y Guidelines, \textit{supra} note 24, at 3871.
adolescent has demonstrated a sustained and persistent pattern of gender nonconformity or gender dysphoria; (3) the adolescent has demonstrated the emotional and cognitive maturity required to provide informed consent for treatment; (4) any coexisting psychological, medical, or social problems that could interfere with diagnosis, treatment, or the adolescent's ability to consent have been addressed; (5) the adolescent has been informed of the reproductive effects of treatment in the context of their stage in pubertal development and discussed fertility preservation options; and (6) the adolescent has reached Tanner stage 2 of puberty to initiate pubertal suppression. Further, a pediatric endocrinologist or other clinician experienced in pubertal assessment must (7) agree with the indication for treatment, (8) confirm the patient has started puberty, and (9) confirm that there are no medical contraindications.

If all of the above criteria are met, the Guidelines instruct that gonadotropin-releasing hormone (GnRH) analogues, or “puberty blockers,” may be offered beginning at the onset of puberty. The purpose of puberty blockers is to delay

32 WPATH Guidelines, supra note 24, at S59–65.
33 Endocrine Soc’y Guidelines, supra note 24, at 3878 tbl.5.
34 WPATH Guidelines, supra note 24, at S64; Martin, Criminalization of Gender-Affirming Care—Interfering with Essential Treatment for Transgender Children and Adolescents, supra note 7.
Pubertal development until adolescents are old enough and have had sufficient time to make more informed decisions about whether to pursue further treatments. Puberty blockers also can make pursuing transition later in life easier, because they prevent irreversible bodily changes such as protrusion of the Adam’s apple or breast growth. Puberty blockers have well-known efficacy and side-effect profiles, and their effects are generally reversible. In fact, puberty blockers have been used by pediatric endocrinologists for more than 40 years for the treatment of precocious puberty. The risks of any serious adverse effects from these treatments are exceedingly rare when provided under clinical supervision.

Later in adolescence—and if the criteria below are met—hormone therapy

35 WPATH Guidelines, supra note 24, at S112.
36 See AAP Policy Statement, supra note 4, at 5.
37 See Martin, supra note 7, at 2.
38 See id.
may be used to initiate puberty consistent with the patient’s gender identity. 41 Hormone therapy involves using gender-affirming hormones to allow adolescents to develop secondary sex characteristics consistent with their gender identity. 42 Hormone therapy is only prescribed when a qualified mental health professional has confirmed the persistence of the patient’s gender dysphoria, the patient’s mental capacity to assent to the treatment, and that any coexisting problems have been addressed. 43 A pediatric endocrinologist or other clinician experienced in pubertal induction must also agree with the indication, and the patient and their parents or guardians must be informed of the potential effects and side effects and give their informed consent. 44 Although some of the changes caused by hormone therapy become irreversible after those secondary sex characteristics are fully developed, others are partially reversible if the patient discontinues use of the hormones. 45

The Guidelines contemplate that the prescription of puberty blockers and/or hormone therapy be coupled with education on the safe use of such medications and

41 Martin, supra note 7 at 2.
42 See AAP Policy Statement, supra note 4, at 6.
43 Endocrine Soc’y Guidelines, supra note 24, at 3878 tbl.5.
44 See id.
45 See AAP Policy Statement, supra note 4, at 5–6.
close monitoring to mitigate any potential risks. 46 Decisions regarding the appropriate treatment for each patient with gender dysphoria are made in consultation with the patient, their parents or guardians, and the medical and mental health care team. There is “no one-size-fits-all approach to this kind of care.”47

B. The Guidelines for Treating Gender Dysphoria Were Developed Through a Robust and Transparent Process, Employing the Same Scientific Rigor That Underpins Other Medical Guidelines.

The Guidelines are the product of careful and robust deliberation following the same types of processes—and subject to the same types of rigorous requirements—as other guidelines promulgated by amici and other medical organizations.

For example, the Endocrine Society’s Guidelines were developed following a 26-step, 26-month drafting, comment, and review process.48 The Endocrine Society imposes strict evidentiary requirements based on the internationally recognized Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.49 That GRADE assessment is then reviewed, re-reviewed, and reviewed

46 See Endocrine Soc’y Guidelines, supra note 24, at 3871, 3876.
47 Martin, supra note 7, at 1.
48 See, e.g., Endocrine Soc’y Guidelines, supra note 24, at 3872–73 (high-level overview of methodology).
49 See Gordon Guyatt et al., GRADE Guidelines: 1. Introduction - GRADE Evidence Profiles and Summary of Findings Tables, 64 J. CLINICAL EPIDEMIOLOGY 383 (2011),
again by multiple, independent groups of professionals.\textsuperscript{50} Reviewers are subject to strict conflict of interest rules, and there is ample opportunity for feedback and debate through the years-long review process.\textsuperscript{51} Further, the Endocrine Society continually reviews its own guidelines and recently determined that the 2017 transgender care guidelines continue to reflect the best, most up-to-date available evidence.

First published in 1979, the WPATH Standards of Care are currently in their 8th Edition. The current Standards of Care are the result of a robust drafting, comment, and review process that collectively took five years.\textsuperscript{52} The draft guidelines went through rigorous review and were publicly available for discussion and debate, receiving a total of 2,688 comments.\textsuperscript{53} 119 authors were ultimately involved in the final draft, including feedback from experts in the field as well as

\begin{flushleft}
\textsuperscript{51} See id.
\textsuperscript{52} See WPATH Guidelines, supra note 24, at S247–51.
\textsuperscript{53} See id.
\end{flushleft}
from transgender individuals and their families.54

C. Scientific Evidence Indicates the Effectiveness of Treating Gender Dysphoria According to the Guidelines.

Multiple studies indicate that adolescents with gender dysphoria who receive gender-affirming medical care experience improvements in their overall well-being.55 Nine studies have been published that investigated the use of puberty blockers on adolescents with gender dysphoria,56 and nine studies have been

See id.

See Martin, supra note 7, at 2.

published that investigated the use of hormone therapy to treat adolescents with gender dysphoria.\textsuperscript{57} These studies find positive mental health outcomes for those adolescents who received puberty blockers or hormone therapy, including statistically significant reductions in anxiety, depression, and suicidal ideation.\textsuperscript{58}

\begin{flushright}
\end{flushright}


\textsuperscript{58} The data likewise indicates that adults who receive gender-affirming care experience positive mental health outcomes. \textit{See, e.g., Zoe Aldridge et al., Long Term Effect of Gender Affirming Hormone Treatment on Depression and Anxiety Symptoms in Transgender People: A Prospective Cohort Study, 9 ANDROLOGY
For example, a 2020 study analyzed survey data from 89 transgender adults who had access to puberty blockers while adolescents and from more than 3,400 transgender adults who did not. The study found that those who received puberty blocking treatment had lower odds of lifetime suicidal ideation than those who wanted puberty blocking treatment but did not receive it, even after adjusting for demographic variables and level of family support. Approximately nine in ten transgender adults who wanted puberty blocking treatment but did not receive it reported lifetime suicidal ideation. Additionally, a longitudinal study of nearly 50 transgender adolescents found that suicidality was decreased by a statistically-significant degree after receiving gender-affirming hormone treatment. A study published in January 2023, following 315 participants age 12 to 20 who received gender-affirming hormone treatment, found that the treatment was associated with decreased symptoms of depression and anxiety.

As another example, a prospective two-year follow-up study of adolescents

59 See Turban, Pubertal Suppression For Transgender Youth And Risk of Suicidal Ideation, supra note 55.
60 See id.
61 See id.
62 See Allen, supra note 56.
63 See Chen, supra note 56.
with gender dysphoria published in 2011 found that treatment with puberty blockers was associated with decreased depression and improved overall functioning. A six-year follow-up study of 55 individuals from the 2011 study found that subsequent treatment with hormone therapy followed by surgery in adulthood was associated with a statistically significant decrease in depression and anxiety. “Remarkably, this study demonstrated that these transgender adolescents and young adults had a sense of well-being that was equivalent or superior to that seen in age-matched controls from the general population.”

As scientists and researchers, amici always welcome more research, including on this crucial topic. However, the available data indicate that the gender-affirming treatments prohibited by the Healthcare Ban are effective for the treatment of gender dysphoria. As the U.S. Court of Appeals for the Eighth Circuit recently recognized in affirming an order preliminarily enjoining enforcement of a similar Arkansas law, “there is substantial evidence … that the [Arkansas] Act prohibits medical treatment

64 See Vries, Puberty Suppression in Adolescents with Gender Identity Disorder: A Prospective Follow-Up Study, supra note 55.
65 Vries, Young Adult Psychological outcome After Puberty Suppression and gender Reassignment, supra note 55.
that conforms with the recognized standard of care.”67

III. The Healthcare Ban Would Irreparably Harm Many Adolescents with Gender Dysphoria By Denying Them the Treatment They Need.

The Healthcare Ban denies adolescents with gender dysphoria in Oklahoma access to medical interventions that are designed to improve health outcomes and alleviate suffering and that are grounded in science and endorsed by the medical community. The medical treatments prohibited by the Healthcare Ban can be a crucial part of treatment for adolescents with gender dysphoria and necessary to preserve their health.

As discussed above, research shows that adolescents with gender dysphoria who receive puberty blockers and/or hormone therapy experience less depression, anxiety, and suicidal ideation. Several studies have found that hormone therapy is associated with reductions in the rate of suicide attempts and significant improvement in quality of life.68 In light of this evidence supporting the connection

67 Brandt ex rel. Brandt v. Rutledge, 47 F.4th 661, 671 (8th Cir. Aug. 25, 2022); see also Brandt v. Rutledge, 551 F. Supp. 3d 882, 890 (E.D. Ark. 2021) (“The consensus recommendation of medical organizations is that the only effective treatment for individuals at risk of or suffering from gender dysphoria is to provide gender-affirming care.”); see also Doe v. Ladapo, -- F. Supp. 3d --, 2023 WL 3833848, at *14 (N.D. Fla. June 6, 2023) (enjoining enforcement of a similar Florida statute and set of rules, finding that “[t]he great weight of medical authority supports these treatments”).

68 See M. Hassan Murad et al., Hormonal Therapy and Sex Reassignment: A Systematic Review and Meta-Analysis of Quality of Life and Psychosocial
between lack of access to gender-affirming care and lifetime suicide risk, banning such care can put patients’ lives at risk.

**CONCLUSION**

For the foregoing reasons, Plaintiffs’ motion for a preliminary injunction should be granted.

---

Dated: June 9, 2023

Respectfully submitted,

[Signature]

Micheal Salem OBA #7876
SALEM LAW OFFICES
101 East Gray St., Suite C
Norman, OK 73069
Phone: (405) 366-1234
msalem@msalemlaw.com

Counsel for Amici Curiae
CERTIFICATE OF SERVICE

I hereby certify that foregoing Brief was served by electronic service upon all ECF participating counsel of record on June 9, 2023.

Michael Salem